Salspera

Leadership

Salspera is managed by an expert team along with a Medical Advisory Panel and Business Advisory Panel. Salspera is operationally supported by external advisors, consultants and service providers to professionally manage the development of the technology, products and the business.

Eddie Moradian, PhD

Chief Executive Officer & Co-Founder

Eddie Moradian is a seasoned executive having founded or co-founded 10 biotech companies over 30 years. He is an experienced investor and operational chief executive of biotech companies involved in the life science research and early-stage drug development sectors, with extensive experience in bringing advanced R&D to market. Since 2004, he has served as CEO of MD Biosciences Innovalora Ltd. He currently serves as CEO of Morwell Holding AG, partner of MD Bioproducts GmbH and MD Doctors Direct GmbH (since 2007), CEO of Blossom Medical LLC (since 2014), co-CEO of Incubology LLC (since 2016), CEO of Kahlo Sciences LLC (since 2020), and director of Prava MedTech LLC (since 2024). He holds a M.Sc. in biotechnology and a Ph.D. in Organic Chemistry/Biotechnology from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Daniel Saltzman, MD, PhD

Chief Medical Officer & Co-Founder

Dr. Daniel Saltzman is a co-founder of Salspera, Inc. and the originator of the company's technology platform. He is a Professor of Surgery and Pediatrics, Chief of the Division of Pediatric Surgery, and the A.S. Leonard Endowed Chair in Pediatric Surgery at the University of Minnesota Medical School, where he has practiced since 2000. He is internationally recognized for his work in bacterial-based cancer therapy, holds 23 patents across 13 countries, and has authored more than 160 scientific publications. He earned his B.S., M.D., and Ph.D. degrees from the University of Minnesota. He completed his surgical residency at the University of Minnesota and a fellowship in Pediatric Surgery at Arkansas Children's Hospital.

Board of Directors

Salspera's Board of Directors brings decades of experience in biopharmaceutical development, corporate governance, and strategic leadership.

Eddie Moradian, PhD

Chief Executive Officer & Co-Founder

Executive Director

Daniel Saltzman, MD, PhD

Chief Medical Officer & Co-Founder

Executive Director

Chuck Garner

Lead Director

Chair, Audit Committee; Member, Compensation & Nomination Committees

Charles Garner brings extensive financial leadership and deep expertise in public company financings to the Salspera Board of Directors. With a career spanning over two decades in life sciences and corporate finance, Mr. Garner recently served as Chief Financial Officer of Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on novel therapies for orphan pulmonary and fibrosis indications. Previously, he served as Chief Financial Officer, Chief Business Officer, and Treasurer for Recro Pharma, Inc. (Nasdaq: REPH), a specialty pharmaceutical company. Mr. Garner's background includes providing strategic and financial advisory services as an independent consultant and serving as a director in the Merchant Banking Group of Burrill & Company, a global financial services firm focused on life sciences. Earlier in his career, he spent nearly a decade in the Healthcare Investment Banking Group of Deutsche Bank Securities, where he specialized in assisting life sciences companies with complex financing and advisory transactions. He began his career in the Business Assurance Group at PricewaterhouseCoopers. Mr. Garner holds a Bachelor of Business Administration with high distinction, concentrating in accounting and finance, from the University of Michigan.

Luisa Ingargiola

Independent Director

Chair, Nomination Committee; Member, Compensation & Audit Committees

Luisa Ingargiola is a highly experienced executive and corporate governance expert with a distinguished track record of serving on public company boards. Currently, she serves as Chief Financial Officer of Avalon GloboCare Corp. (Nasdaq: ALBT), a publicly listed biotech healthcare company. Previously, she co-founded MagneGas Corporation, where she served as Chief Financial Officer for over a decade. Ms. Ingargiola is a recognized leader in audit and financial oversight, currently serving as a board member and Audit Committee Chair for several public companies, including BioCorRx Inc., Vision Marine Technologies, Inc., Dragonfly Energy Holdings, and Fusion Fuel Green PLC. Her extensive board experience also includes previous roles with Xos, Inc., Progress Acquisition Corporation, Siyata Mobile, and AgEagle Aerial Systems Inc. She holds an M.B.A. in Health from the University of South Florida and a B.S. in Finance from Boston University.

David Schaffer, PhD

Independent Director

Chair, Compensation Committee; Member, Nomination Committee

Dr. David Schaffer is a globally recognized leader in biotechnology, gene therapy, and stem cell research. Since 1995, he has served as a professor of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cell Biology at the University of California, Berkeley. In 2022, he was appointed Director of QB3, Bakar Labs, and the Bakar Fellows Program at UC Berkeley. Dr. Schaffer's pioneering research applies engineering principles to gene and stem cell therapies, including the development of advanced viral vectors. Technologies developed in his laboratory have been evaluated in over ten human clinical trials. A prolific scientist and entrepreneur, Dr. Schaffer has authored over 250 scientific publications, holds more than 50 issued patents, and has co-founded several successful biotechnology companies, including 4D Molecular Therapeutics (Nasdaq: FDMT), Ignite Immunotherapies (acquired by Pfizer), and Rewrite (acquired by Intellia Therapeutics). He has been elected to both the National Academy of Engineering and the National Academy of Inventors. Dr. Schaffer brings significant public company expertise to Salspera, having previously served on the boards of uniQure Inc. and 4D Molecular Therapeutics. He earned a B.S. in Chemical Engineering from Stanford University and a Ph.D. in Chemical Engineering from MIT, followed by a postdoctoral fellowship at the Salk Institute for Biological Studies.

* Independent directors anticipated to be retained at the IPO.

Scientific Advisory Board

Our Scientific Advisory Board comprises world-class researchers and clinicians who guide the scientific and clinical development of Salspera's therapeutic programs.

Daniel Saltzman, MD, PhD

University of Minnesota

Pediatric Surgery & Oncology

Gerald Batist, MD

McGill University / Jewish General Hospital

Oncology & Translational Cancer Research

Dr. Gerald Batist is Director of the Department of Oncology at the Segal Cancer Centre, Deputy Director of the Lady Davis Institute, and Professor of Oncology at McGill University. He is former Chair of the McGill University Department of Oncology and Director of the McGill Centre for Translational Research in Cancer. Dr. Batist has made significant contributions to the development of new cancer treatments, with research programs focused on novel therapeutics, biomarker discovery, mechanisms of resistance, and new drug discovery. He was elected to the Royal Society of Canada in 2025.

Mitesh J. Borad, MD

Mayo Clinic

Oncology & Gene Therapy

Dr. Mitesh Borad is an internationally recognized oncologist and Professor of Medicine at the Mayo Clinic College of Medicine. He is a leader in novel cancer therapeutic platforms leveraging genomic medicine and gene and virus therapies, with a focus on tumors of the liver, bile ducts, and pancreas. Dr. Borad led clinical development of novel anticancer agents in more than 50 first-in-human studies and was among the first to apply whole-genome sequencing in clinical cancer care. His work contributed to FDA approval of three FGFR inhibitors for cholangiocarcinoma. He is a recipient of the NIH New Innovator Award and the Mark R. Clements Award for Vision, Innovation and Collaboration.

Talia Golan, MD

Sheba Medical Center, Israel

Pancreatic Cancer & Precision Oncology

Prof. Talia Golan is Medical Director of the Phase I Clinical Trial Unit and the Sheba Pancreatic Cancer Program at Chaim Sheba Medical Center in Israel. She is a leading physician-scientist dedicated to studying pancreatic cancer, especially in patients with inherited BRCA1/2 gene mutations. Under her leadership, the Sheba Pancreatic Cancer Translational Research Lab has become a hub for innovative pancreatic cancer research. Prof. Golan's work focuses on understanding resistance mechanisms to platinum-based chemotherapy and PARP inhibitors, and developing new combination strategies to improve outcomes for patients with BRCA1/2-associated pancreatic cancer.

Richard L. Schilsky, MD

ASCO / University of Chicago

Clinical Oncology & Drug Development

Dr. Richard Schilsky is Professor Emeritus of Medicine at the University of Chicago, where he spent nearly 30 years as a clinical oncologist and researcher. He served as the first Chief Medical Officer of the American Society of Clinical Oncology (ASCO) from 2013 to 2021. Dr. Schilsky is the Principal Investigator of the ASCO TAPUR study, a precision oncology basket trial evaluating targeted therapies in patients with advanced cancers. He is a Fellow of ASCO and has made landmark contributions to the clinical development of chemotherapy agents, including fluorouracil and leucovorin combinations in colorectal cancer.

Barry P. Sleckman, MD, PhD

University of Alabama at Birmingham

Cancer Biology & Immunology

Dr. Barry Sleckman is Director of the UAB O'Neal Comprehensive Cancer Center, Alabama's only NCI-designated Comprehensive Cancer Center. He is a world-renowned researcher focused on understanding how DNA double-strand breaks are generated and repaired — a topic critical for cancer and immune system development. Dr. Sleckman completed his M.D. and Ph.D. in immunology at Harvard Medical School, followed by residency at Brigham and Women's Hospital and postdoctoral training at Boston Children's Hospital. He previously served as Associate Director of the Meyer Cancer Center at Weill Cornell Medicine and the Siteman Cancer Center at Washington University.

Christopher Moertel, MD

University of Minnesota

Pediatric Neuro-Oncology

Dr. Christopher Moertel is the Kenneth and Betty Jayne Dahlberg Professor of Pediatrics at the University of Minnesota School of Medicine, Medical Director of the Katie Hageboeck Children's Cancer Research Fund Clinic, and leader of the Pediatric Brain Tumor Program. He has sponsored at least 5 INDs and conducted multiple investigator-initiated clinical trials. His research interests include treatment of Neurofibromatosis-associated neoplasia, targeted therapy of pediatric brain tumors, and immunotherapy of high-grade glioma. He has research collaborations in cancer genomics, cancer immunotherapy, and cancer epidemiology.